|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM26988212X |
| 003 |
DE-627 |
| 005 |
20250221085616.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2017 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.2144/000114525
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0899.xml
|
| 035 |
|
|
|a (DE-627)NLM26988212X
|
| 035 |
|
|
|a (NLM)28298179
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Bethune, Michael T
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran doping
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 24.10.2017
|
| 500 |
|
|
|a Date Revised 06.03.2018
|
| 500 |
|
|
|a published: Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Peptide-major histocompatibility complex (pMHC) multimers enable the detection, characterization, and isolation of antigen-specific T-cell subsets at the single-cell level via flow cytometry and fluorescence microscopy. These labeling reagents exploit a multivalent scaffold to increase the avidity of individually weak T-cell receptor (TCR)-pMHC interactions. Dextramers are an improvement over the original streptavidin-based tetramer technology because they are more multivalent, improving sensitivity for rare, low-avidity T cells, including self/tumor-reactive clones. However, commercial pMHC dextramers are expensive, and in-house production is very involved for a typical biology research laboratory. Here, we present a simple, inexpensive protocol for preparing pMHC dextramers by doping in biotinylated dextran during conventional tetramer preparation. We use these pMHC dextramers to identify patient-derived, tumor-reactive T cells. We apply the same dextran doping technique to prepare TCR dextramers and use these novel reagents to yield new insight into MHC I-mediated antigen presentation
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a T-cell receptor (TCR)
|
| 650 |
|
4 |
|a biotinylated dextran
|
| 650 |
|
4 |
|a cancer immunotherapy
|
| 650 |
|
4 |
|a dextramer
|
| 650 |
|
4 |
|a immunology
|
| 650 |
|
4 |
|a ligand discovery
|
| 650 |
|
4 |
|a major histocompatibility complex (MHC)
|
| 650 |
|
4 |
|a multimer
|
| 650 |
|
4 |
|a pMHC
|
| 650 |
|
4 |
|a peptide
|
| 650 |
|
4 |
|a peptide-specific MHC clustering
|
| 650 |
|
4 |
|a tetramer
|
| 650 |
|
4 |
|a tumor antigen discovery
|
| 650 |
|
7 |
|a Dextrans
|2 NLM
|
| 650 |
|
7 |
|a Fluorescent Dyes
|2 NLM
|
| 650 |
|
7 |
|a Histocompatibility Antigens
|2 NLM
|
| 650 |
|
7 |
|a Peptides
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Antigen, T-Cell
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Fusion Proteins
|2 NLM
|
| 650 |
|
7 |
|a Biotin
|2 NLM
|
| 650 |
|
7 |
|a 6SO6U10H04
|2 NLM
|
| 650 |
|
7 |
|a Streptavidin
|2 NLM
|
| 650 |
|
7 |
|a 9013-20-1
|2 NLM
|
| 700 |
1 |
|
|a Comin-Anduix, Begoña
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hwang Fu, Yu-Hsien
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ribas, Antoni
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Baltimore, David
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t BioTechniques
|d 1991
|g 62(2017), 3 vom: 01. März, Seite 123-130
|w (DE-627)NLM012627046
|x 1940-9818
|7 nnas
|
| 773 |
1 |
8 |
|g volume:62
|g year:2017
|g number:3
|g day:01
|g month:03
|g pages:123-130
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.2144/000114525
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_21
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_62
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_99
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_618
|
| 912 |
|
|
|a GBV_ILN_640
|
| 912 |
|
|
|a GBV_ILN_754
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2002
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2007
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2009
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2015
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 912 |
|
|
|a GBV_ILN_2023
|
| 912 |
|
|
|a GBV_ILN_2035
|
| 912 |
|
|
|a GBV_ILN_2040
|
| 912 |
|
|
|a GBV_ILN_2060
|
| 912 |
|
|
|a GBV_ILN_2099
|
| 912 |
|
|
|a GBV_ILN_2105
|
| 912 |
|
|
|a GBV_ILN_2121
|
| 912 |
|
|
|a GBV_ILN_2470
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 62
|j 2017
|e 3
|b 01
|c 03
|h 123-130
|